Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 17/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 14/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26074350 | 0.89 | LMNA (0.58) | RAF1LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26074474 | 0.87 | LMNA (0.50) | RAF1LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26075596 | 0.83 | BRAF (0.56) | RAF1BRAF | |
| SCHEMBL26075758 | 0.82 | RAF1 (0.58) | RAF1LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25984211 | 0.82 | RAF1 (0.51) | RAF1BRAF | |
| SCHEMBL26075759 | 0.81 | BRAF (0.47) | RAF1BRAF | |
| SCHEMBL26075769 | 0.79 | BRAF (0.42) | RAF1BRAF | |
| SCHEMBL29272102 | 0.76 | RAF1 (0.53) | RAF1BRAF | |
| SCHEMBL30237169 | 0.76 | RAF1 (0.53) | RAF1BRAF | |
| SCHEMBL26074353 | 0.75 | GAA (0.53) | RAF1NPC1RAB9ASMN1; SMN2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | RAF1 115/4885LMNA 3263/4885NPC1 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.